Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Division of Biopharmaceutics and Pharmacokinetics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, 410013, China.
Int J Antimicrob Agents. 2022 Jun;59(6):106600. doi: 10.1016/j.ijantimicag.2022.106600. Epub 2022 May 6.
The appropriateness of the Hartford nomogram based on 7 mg/kg gentamicin with administration interval adjustment is questioned in critically ill patients. This study aimed to perform a pharmacokinetic/pharmacodynamic (PK/PD) evaluation of the Hartford nomogram and to assess the influence of PK/PD indices on gentamicin dosing. Gentamicin data were extracted from a critical care database to construct the population PK model. Simulations were performed to evaluate the probability of target attainment (PTA) and risk of toxicity for the gentamicin Hartford nomogram. C/MIC ≥ 10 and AUC/MIC ≥ 100 were the PK/PD targets considered, and the non-toxicity targets included concentration < 0.5 mg/L for at least 4 h within a dosing interval and trough concentration < 1 mg/L. A one-compartment model was optimal to describe gentamicin PKs, and creatinine clearance (CL) was included as a time-varying covariate on gentamicin clearance. The PTA of C/MIC ≥ 10 (MIC = 1 mg/L) for the Hartford nomogram was suboptimal after the first dose but was desirable (near or greater than 90%) at steady-state, and > 90% PTA based on AUC/MIC ≥ 100 was readily achieved after the first dose in patients with CL < 60 mL/min. Significant PTA differences between the PK/PD targets were observed at an MIC of 2 mg/L, but the PTAs were all low. The predicted risk of toxicity was high regardless of the applied toxicity targets. The Hartford nomogram provided adequate gentamicin exposure in critically ill patients with an MIC ≤ 1 mg/L by considering the combined PK/PD indices.
基于 7mg/kg 庆大霉素调整给药间隔的哈特福德诺模图在危重症患者中的适用性受到质疑。本研究旨在对哈特福德诺模图进行药代动力学/药效学(PK/PD)评估,并评估 PK/PD 指标对庆大霉素给药的影响。从一个重症监护数据库中提取庆大霉素数据来构建群体 PK 模型。进行模拟以评估哈特福德诺模图的目标浓度达标率(PTA)和毒性风险。考虑的 PK/PD 目标为 C/MIC≥10 和 AUC/MIC≥100,非毒性目标包括在给药间隔内至少 4 小时内浓度<0.5mg/L 和谷浓度<1mg/L。单室模型最适合描述庆大霉素 PK,肌酐清除率(CL)被用作庆大霉素清除率的时变协变量。首次给药后,哈特福德诺模图的 C/MIC≥10(MIC=1mg/L)的 PTA 并不理想,但在稳态时是理想的(接近或大于 90%),对于 CL<60mL/min 的患者,首次给药后基于 AUC/MIC≥100 的 PTA 很容易达到>90%。在 MIC 为 2mg/L 时,观察到 PK/PD 目标之间存在显著的 PTA 差异,但 PTA 均较低。无论应用何种毒性目标,预测的毒性风险都很高。通过考虑联合 PK/PD 指标,哈特福德诺模图为 MIC≤1mg/L 的危重症患者提供了足够的庆大霉素暴露。